MedTrace Logo

Biomarker Study in Pancreatic Neuroendocrine Tumours

NCT03130205 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-08-25

No results posted yet for this study

Summary

The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.

Conditions

Interventions

PROCEDURE

Core Needle Biopsy

Core Needle Biopsy is performed from liver metastasis.

RADIATION

Computed Tomography

Computed Tomography

RADIATION

18F-FDG-PET

18F Fluorodeoxyglucose Positron emission tomography

PROCEDURE

Phlebotomy

3 EDTA tubes drawn from peripheral vein

GENETIC

Molecular genetic analysis

Performed on biomaterial from peripheral vein and core needle biopsy

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Principal Investigators

  • Barbro Eriksson, MD PhD · Akademiska Sjukhuset, Uppsala

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2021-01-01
Completion
2022-01-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03130205 on ClinicalTrials.gov